Sagimet Biosciences Inc. 4

Insider Kemble George exercised options and sold 20,206 shares of Sagimet Biosciences Inc. Series A Common Stock on August 11, 2026 for about $201,246 in total proceeds under a Rule 10b5-1 plan.

On August 11, 2026, Sagimet Biosciences Inc. insider Kemble George exercised two tranches of stock options for a total of 20,206 shares of Series A Common Stock at an exercise price of $6.36 per share and immediately sold all 20,206 shares at a weighted average price of approximately $9.9548 under a Rule 10b5-1 trading plan adopted on August 21, 2025, resulting in gross sale proceeds of roughly $201,246. After these transactions, which included the exercise of options at no remaining option value reported and the disposition of the underlying shares, George reported direct ownership of 62,161 shares of Series A Common Stock. The option awards were already fully vested and exercisable as of the transaction date, and the sale prices ranged from $9.95 to $9.99 per share.

Filing Facts

CIK

1400118

Ticker

SGMT

Form

4

Source Type

fda

Accession

0001193125-26-347407

Alert Tier

5